Ready to use Parkinson’s stem cell therapy put on FDA fast track

In trial, treatment showed benefits in those with early-onset disease

Written by Margarida Maia, PhD | Aug. 10, 2026

• The U.S. Food and Drug Administration has awarded fast track status to an experimental stem cell therapy for Parkinson's disease.
• XS411 is a ready-to-use therapy designed to replace lost dopamine-producing nerve cells and restore neurological function in patients.
• The treatment candidate is now being tested for early Parkinson's in a clinical trial in China.

An off-the-shelf, or ready to use, stem cell therapy that’s designed to replace the nerve cells lost in Parkinson’s disease and restore neurological function has been put on a developmental fast track by the U.S. Food and Drug Administration (FDA).

The FDA awarded fast track status — a designation that could mean a faster pathway through regulatory review if clinical data are positive — to XS411, being developed by China-based Xellsmart. Clinical trials have already been cleared in both China and the U.S. to test the injection therapy.

According to the developer, a Phase 1/2 study (NCT07166757) in China has shown benefits with the therapy’s use in people with early-onset Parkinson’s.

In a company press release, Xellsmart called the new U.S. designation a “key milestone for [the] global clinical development” of XS411. Such status offers more frequent communication with the FDA and access to rolling review, which means parts of the data can be submitted as they become available rather than waiting until the full package is ready before filing for approval.